“Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection” project has officially launched Phase II clinical trials.
The “Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection” project, independently developed by our company, has officially launched its Phase II clinical trial. This trial is led by Xuanwu Hospital of Capital Medical University and is being conducted at several renowned research institutions across the country. Currently, the first subject has been enrolled in the trial, and the first dose was administered on March 19.



